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Abstract
Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-
Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-
TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study
is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from
healthy individuals.
Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals,
were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63
from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including
43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30
from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on
weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made
using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally
determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an
electrochemiluminescent immunoassay.
Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a
biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test
set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The
sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower
than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test
set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small
cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung
cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.
Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients,
especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the
SELDI-TOF-MS is a potential tool for the screening of lung cancer.
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Lung cancer is, at present, the most common malignancy
in the world and its overall 5-year survival rate is only
14% [1]. The poor prognosis is due largely to lack of suf-
ficient screening and early diagnostic tools to physicians.
Currently in clinic the screening and early diagnosis of
lung cancer relies mainly on chest X-ray, low-dose com-
puted tomography, bronchoscopy, sputum cytology, and
tumor markers including carcinoembryonic antigen
(CEA), cytokeratin-19 fragments (Cyfra21-1), carbohy-
drate antigen 19-9 (CA19-9), squamous cell carcinoma
antigen (SCCAg) and neuron-specific enolase (NSE), etc
[2]. All these methods, however, lack adequate sensitivity
and/or specificity [3-6]. Thus, it is urgent to search for bet-
ter methods which provide more valuable information for
screening and early diagnosis of lung cancer. Because of
the marked heterogeneity of lung cancer [5], a panel of
biomarkers for screening and diagnosis would be most
appropriate. Surface-Enhanced Laser Desorption /ioniza-
tion Time-of-Flight Mass Spectrometry (SELDI-TOF-MS),
an innovative proteomic technology introduced by
Hutchens and Yip [7], has overcome many of the limita-
tions of two-dimensional electrophoresis and Matrix-
Assisted Laser Desorption/ionization Time-of-Flight Mass
Spectrometry (MALDI-TOF-MS) [8,9]. This is a high
through-put technique for analysis of complex biological
specimens such as serum. It can detect multiple protein
changes simultaneously with high sensitivity and specifi-
city [10,11]. Recently, SELDI has been successfully used to
distinguish pancreatic, ovarian and prostate cancer
patients from controls [9,12,13], and detect markers of
bladder cancer in urine [14].
The aim of the current study was to investigate the appli-
cation of serum SELDI protein profiling to distinguish
lung cancer patients from a healthy population.
Methods
Patients
A total of 208 serum samples including 158 pathologi-
cally confirmed lung cancer patients and 50 healthy sub-
jects were collected from the Department of Respiratory
and Thoracic Surgery of the Second Hospital of Xi'an Jia-
otong University. Informed consent was obtained from
every subject prior to the study. All patients with lung can-
cer were found to have no evidence of other disease. The
distribution of clinical stages (UICC, 1997) was as fol-
lows: 13 cases were at stage I, 41 stage II, 58 stage III, 46
stage IV. Among these patients, 68 patients suffered from
squamous cell carcinomas, 53 from adenocarcinomas, 35
from small cell cancers and 2 from bronchioloalveolar
carcinomas. The average age of the patients (101 males,
57 females ranging from 28 to 79 years) was 56.8. The
healthy controls (31 males, 19 females ranging from 30
to72 years) came from general physical examinations, and
had an average age of 54.5. The two groups were matched
for age, sex and smoking history. Two milliliters of whole
blood were collected during fasting and stored within one
hour at 4°C. The blood was later centrifuged for 20 min at
4000 rpm, distributed into 100 µl aliquots, and stored at
-80°C until used.
SELDI protein profiling
Five µL of 10 mM HCl was applied to a weak cation
exchange (WCX2) chip and placed at room temperature
for 10 min. Chips were rinsed with deionized water in a
conical tube and then put into a bioprocessor and washed
with binding buffer (100 mM NaAc, pH4) with gentle
shaking twice for 5 min. Five µL of each serum and 10 µL
of 9 mol/L urea were combined and vortexed on ice. 5 µL
of this mixture was added to 60 µL of binding buffer. 50
µL of the serum mixture was applied to each spot and
incubated on a shaker for 60 min. Chips were washed
again with binding buffer with slight shaking 3 times. 200
µL of 1 mM HEPES pH7.0 was added to each well. Wells
were quickly rinsed and then removed and let dry. Once
dry, 0.5 µL of sinapinic acid (SPA) was applied to each
spot twice. The arrays were allowed to air-dry and then
stored in the dark at RT until SELDI analysis.
Data analysis
Before analysis, the data were randomly divided into two
sets as follows: the training set consisted of 11 patients
with stages I/II lung cancer, 63 patients with stages III/IV
lung cancer and 20 healthy controls. The blinded test (in
which the disease status was unrevealed) set consisted of
43 patients with stages I/II lung cancer, 41 patients with
stages III/IV lung cancer and 30 healthy controls. The
chips were placed in the Protein Biological system II-C
mass spectrometer reader (Ciphergen Biosystems, Inc.)
and TOF spectra were generated by averaging 128 laser
shots with an intensity of 215 and a detector sensitivity of
9. The optimization range was from 3,000 to 50,000 Da,
and a maximum of 200,000 Da. External calibration of
the instrument was performed using the All-in-one pep-
tide molecular mass standard (Ciphergen Biosystems,
Inc.). We achieved a mass accuracy of 0.1% with this
system.
Peak detection
Peak detection using Ciphergen Biomarker Wizard soft-
ware 3.0.2 identified an average of 72 peaks/spectrum. Of
the 72 peaks, 64 common peaks or clusters were generated
from the training set. Eighteen of these proteins were
found to have statistically differential expression levels
between lung cancer and normal control sera (P < 10-4).
Peak detections involved baseline subtraction, mass accu-
racy calibration, and automatic peak detection. The set-
tings used for our work were as follows: for peak detection
the signal-to-noise ratio was 3, minimum peak thresholdPage 2 of 7
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0.5% and the signal-to-noise ratio for the second pass was
1.
Decision tree classification
Construction of the decision tree classification algorithm
was performed by Ciphergen Biomarker Pattern software
version 5.0. Classification tree, selected Gini, split the data
into two nodes using one rule at a time in the form of peak
intensity. The splitting decisions in this case were based on
the normalized intensity levels of peaks from SELDI pro-
tein expression profile. The process of splitting was contin-
ued until terminal nodes were created. After V-fold cross
validation 50, the accuracy of each classification tree was
then challenged with the blinded test set.
Classification of lung cancer vs. normal samples by the decision tree algorithmFigure 1
Classification of lung cancer vs. normal samples by the decision tree algorithm. The left branch node after the first 
layer is the cases of peak intensity under 2.018, the right one is over or equal to 2.018. The cutoff points for 8245, 6429 and 
2538 Da were 1.574, 49.64 and 13.01, respectively. The cutoff points of mass 5335 Da were 0.288 (left) and 2.163 (right). N 
represents the number of samples. M represents the molecular weight.Page 3 of 7
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The two markers, Crfra21-1 and NSE, were measured in
the 208 sera included in this study using an electrochem-
iluminescent immunoassay (ECLIA, Elecsys 2010 system,
Roche Diagnostics, Switzerland). The cutoff values for
Crfra21-1 and NSE, recommended by the manufacturers,
were 3.3 ng ml-1and 16.3 ng ml-1, respectively.
Statistical analysis
Comparison of relative peak intensity levels between
groups was made using the Student's t test and in all cases
P < 10-4 was considered statistically significant. Compari-
son of rates between groups was conducted using the χ2
test and P < 0.05 was regarded as a significant difference.
Results
Reproducibility
The reproducibility of each SELDI proteinchip assay was
determined by SELDI profiling of 10 aliquots of pooled
normal serum. The average coefficient of variance (CV)
based on 10 pooled normal human sera for intensities of
22 randomly chosen peaks was less than 20%. Little vari-
ation with day-to-day sampling and instrumentation or
chip variations was found.
Serum SELDI profiles of lung cancers versus healthy 
controls
Using Ciphergen Biomarker pattern software to analyze
the data derived from Ciphergen Biomarker wizard soft-
ware, approximately 64 peaks per spectrum identified in
the training set were determined with masses ranging
from 3–30 kDa. We found that no single peak could ade-
quately discriminate lung cancer sera from normal sera.
Using all 64 peaks, a decision tree classification algorithm
was built and five protein peaks at 11493, 8245, 5335,
6429 and 2538 Da were automatically selected as splitters.
The 11,493 Da peak was used as the root node in the clas-
sification tree to divide the 94 samples into two groups
(Fig. 1): the left node (node 2) included cases with peak
intensity < 2.018. The right node (node 6) contained the
remaining with peak intensity = 2.018. The cases in each
branch node were then reclassified at the next layer fol-
lowing the same process with 6429, 5335, 2538 and 8245
Da as splitters. This splitting process stops if terminal
nodes for further splitting have no gain. Finally, all 94
cases in the training set were classified in the 7 terminal
nodes, and a classification tree was obtained (Fig. 1). The
tree correctly classified 95.9% of the lung cancer sera in
the training set (Table 1). The validity of this classification
tree algorithm was then challenged with the test set and a
total of 80.0% of controls and 86.9% of lung cancer sam-
ples were correctly identified (Table 1). Based on the
results of the test set we calculated the sensitivity of the
SELDI marker pattern in the detection of lung cancers
with different stages and pathological types (Table 2). The
peaks at 11493 and 5335 Da are shown in Fig. 2. Aside
from the 11493 Da peak, any of the other 5 peaks could
have been used as the first node in the classification trees
in the same way as 11493 Da, but their performance
scores were inferior to the 11493Da peak.
Table 1: Classification tree analysis of the lung cancer training and blinded test sets.
Sets Groups Percentage correct Percentage misclassified
Training set Normal (n = 20) 90.0 % (18/20) 10.0% (2/20)
Cancer (74) 95.9% (71/74) 4.1% (3/74)
Blinded test set Normal (30) 80.0% (24/30) 20.0% (6/30)
Cancer (84) 86.9% (73/84) 13.1% (11/84)
Table 2: The sensitivity of the SELDI marker pattern in lung cancer patients with different stages and pathological types.
Variables n Correct cases Error cases Sensitivity (%) P value
Clinical stages
I/II 43 34 9 79.1
III/IV 41 39 2 95.1 <0.05
Pathological types
NSCLC 70 64 6 91.4
SCLC 14 9 5 64.3 <0.05
NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer.Page 4 of 7
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Table 3 provides the results of sensitivities and specifici-
ties of Cyfra21-1 and NSE used individually and com-
bined. We compared the diagnostic capacities of the
SELDI marker pattern with Cyfra21-1 and NSE individu-
ally and combined (Table 3).
Differential expressions of the SELDI peaks at 11493 (group A) and 5335Da (group B) in the comparisons of lung cancer and healthy control s raFigu  2
Differential expressions of the SELDI peaks at 11493 (group A) and 5335Da (group B) in the comparisons of 
lung cancer and healthy control sera. a-c: squamous cell carcinomas; d-f: adenocarcinomas; g-i: small cell carcinomas; j-l, 
healthy controls. X-axis was molecular weight of peak; Y-axis was intensity of peak.
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Currently, there are no satisfactory screening and early
diagnostic strategies for lung cancer. SELDI is a high
through-put technique used to generate protein expres-
sion profiles which, in combination with bioinformatics
tools to extract information for biomarker discovery, has
been essential in identifying novel protein biomarkers.
Indeed, application of this technology has shown great
potential for the early detection of ovarian and prostate
cancers [10,12].
Proteomic studies of lung cancer are still scarce [15].
Recently, Xiao, et al [16] reported that a proteomic panel
consisting of three protein peaks yielded a sensitivity of
93.3% and specificity of 96.7% in distinguishing lung
cancer patients from healthy controls. This study was,
however, based on only 45 tumor samples. In the present
study, we examined 158 serum samples from lung cancer
patients and 50 from healthy individuals using the SELDI
technique with the WCX2 proteinchip. The classification
tree was constructed to distinguish lung cancer cases from
healthy individuals using 5 protein peaks at 11493, 6429,
8245, 5335 and 2538 Da as a marker pattern. When the
model was tested with the blinded test set, it yielded a sen-
sitivity of 86.9%, specificity of 80.0%, and positive predic-
tive value of 92.4% (73/79). For comparison, Cyfra21-1
and NSE were measured using ECLIA in our study.
Although there is no statistical differences between the
specificities of Cyfra21-1, NSE and the SELDI marker pat-
tern, the sensitivity achieved by Cyfra21-1, NSE individu-
ally or in combination were significantly lower than that
of the SELDI pattern. These results indicate that the SELDI
pattern is distinctly superior to Cyfra21-1 and NSE indi-
vidually or combined in distinguishing lung cancer
patients from healthy individuals.
Based on the results of the blinded test set, we found that
the sensitivity of the SELDI marker pattern for NSCLCs
was significantly higher than for SCLCs, indicating that
the pattern may be more effective in discriminating
NSCLC patients from healthy controls than SCLC
patients. Similarly, the pattern also had a sensitivity of
79.1% in the detection of lung cancers with stages I/II,
suggesting that the pattern might be better for early detec-
tion of lung cancer than any other single or panel of
biomarkers currently used in clinic [17,18].
To develop a broad biomarker panel for screening a
diverse, high-risk population, both NSCLC and SCLC
patients were chosen for our study. Due to the relatively
fewer healthy control samples and the subgroup of
patients with SCLC, our results require more samples to
broaden and improve its diagnostic value. Furthermore,
the five proteins included in the SELDI marker pattern
will be identified by MALDI-MS-MS.
Conclusion
We have found that serum SELDI protein profiling can
distinguish lung cancer patients, especially NSCLC
patients, from healthy controls with relatively high sensi-
tivity and specificity. The SELDI-TOF-MS is a potential
tool for the screening of lung cancer.
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Table 3: The sensitivities and specificities of the SELDI marker pattern, Cyfra21-1 and NSE.
Items Pattern Cyfra21-1 NSE Combination
Blinded test set
Sensitivity (%) 86.9 (73/84) 44.0(37/84)a 36.9(31/84)a 63.1(53/84)a
Specificity (%) 80.0 (24/30) 70.0(21/30) 73.3(22/30) 53.3(16/30) b
Whole set
Sensitivity (%) 46.2 (73/158) 35.4 (56/158) 62.0 (98/158)
Specificity (%) 72.0 (36/50) 74.0 (37/50) 56.0 (28/50)
Pattern: SELDI marker pattern; Combination: combined use of Cyfra21-1 and NSE. a P < 0.005 compared with the SELDI marker pattern; b P < 0.05 
compared with the SELDI marker pattern.Page 6 of 7
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